Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

Dose-response relationship. ***Dose-response relationship*** - The **dose-response relationship** (particularly the **graded dose-response curve**) describes how the magnitude of a drug's effect changes with different doses. - When plotted for different individuals or populations, these curves reveal **variation in sensitivity** through differences in potency (horizontal shift) and efficacy (maximum response). - This relationship helps characterize inter-individual variability in drug response and is the fundamental concept for understanding differential sensitivity. *Therapeutic index* - The **therapeutic index** is a measure of drug safety, representing the ratio between the toxic dose and the effective dose (TD50/ED50 or LD50/ED50). - It does not directly explain the variation in sensitivity to different doses among individuals, but rather provides information about the drug's overall safety margin. *Bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the systemic circulation unchanged. - While it influences the drug concentration at the site of action, it doesn't directly measure the variability in physiological response to that concentration among individuals. *Phase 1 clinical trials* - **Phase 1 clinical trials** are the first stage of testing a new drug in humans, primarily focusing on safety, dosage range, and pharmacokinetics in a small group of healthy volunteers. - While variability in response may be observed during these trials, they are not the *pharmacological concept* that describes this variation; rather, dose-response relationships are used to interpret findings from these trials.

Q: A drug with high plasma protein binding property has which of the following properties?

Lower volume of distribution. ***Lower volume of distribution*** - Drugs with high plasma protein binding are largely confined to the **vascular compartment** as they bind to proteins (e.g., albumin, alpha-1-acid glycoprotein), making them less available to distribute into tissues. - This confinement within the plasma compartment results in a **smaller apparent volume of distribution**. *Less drug interaction* - High plasma protein binding actually increases the potential for **drug-drug interactions** through displacement. - If a second drug displaces the first from its binding sites, it can increase the **free fraction** and potentially lead to toxicity. *Reduced renal clearance* - While highly protein-bound drugs are generally not easily filtered by the glomeruli, their primary route of elimination is often through **hepatic metabolism** or **active tubular secretion**, rather than reduced renal elimination. - Many highly protein-bound drugs still undergo significant renal excretion via **active secretion**, if they are substrates for active transporters. *Less tubular secretion* - Plasma protein binding does not inherently reduce tubular secretion; in some cases, the drug-protein complex can dissociate rapidly at the secretory sites, allowing for efficient secretion of the **free drug**. - In fact, many drugs that undergo significant tubular secretion are also highly protein-bound, as protein binding helps **maintain a concentration gradient** for and delivery of the drug to the secretion transporters.

Q: When alcohol is consumed with aerated soft drinks -

Absorption is faster, increasing intoxication risk. ***Absorption is faster, increasing intoxication risk*** - The carbonation in aerated soft drinks speeds up the absorption of alcohol into the bloodstream. - This **faster absorption** leads to a more rapid increase in blood alcohol concentration and can intensify the effects of alcohol, thereby increasing the risk of intoxication. *Effect is enhanced* - While the **effect** might seem to be enhanced due to quicker onset, this option doesn't fully explain the physiological mechanism. - The primary reason for the perceived enhancement is the **accelerated absorption**, not a direct potentiation of alcohol's action. *To reduce hangover risk* - Mixing alcohol with aerated drinks generally **does not reduce hangover risk**; in fact, the rapid absorption can sometimes worsen dehydration and lead to a more severe hangover. - Hangovers are primarily caused by dehydration, acetaldehyde buildup, and other congeners, which are not mitigated by carbonated mixers. *None of the options* - This option is incorrect because the statement about **faster absorption leading to increased intoxication risk** is a well-established physiological effect.

Q: Which of the following statements represents the most clinically significant aspect of drug metabolism?

Most common enzyme involved is CYP 3A4/5. ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.

Q: High volume of distribution is primarily determined by:

High lipid solubility. ***High lipid solubility***- Highly **lipid-soluble** drugs readily cross biological membranes and distribute extensively into tissues, including adipose tissue, CNS, and intracellular compartments, leading to a **high volume of distribution (Vd)** [1, 2].- This property allows the drug to move out of the bloodstream and into various body compartments, increasing the apparent volume in which the drug is dissolved [1].*High plasma protein binding*- **High plasma protein binding** generally **restricts** drug distribution to tissues because only the **unbound (free) fraction** can diffuse across capillary membranes into interstitial fluid and cells [1].- This typically leads to a **lower Vd**, as the drug is largely retained within the plasma compartment.*Elimination rate*- The **elimination rate** determines how quickly the drug is removed from the body, affecting the **duration of action** rather than the extent of distribution.- It influences drug concentration changes over time but does not directly determine the physical space (volume) into which the drug distributes.*Half-life of the drug*- The **half-life (t½)** is the time required for drug concentration to reduce by half, and it is **determined by** both Vd and clearance (t½ = 0.693 × Vd/CL).- Half-life is a **consequence** of Vd and clearance, not a primary determinant of how widely a drug distributes [3].

Q: Where does the oxidation of drugs mainly take place?

Smooth ER. **Smooth ER** - The **smooth endoplasmic reticulum (SER)** is rich in enzymes, particularly the **cytochrome P450 system**, which is primarily responsible for phase I **oxidation reactions** of many drugs and xenobiotics [1]. - These oxidative reactions typically **increase the polarity** of drugs, making them easier to excrete [1]. *Nucleus* - The nucleus primarily contains the cell's **genetic material** (DNA) and is involved in **gene expression** and replication. - It does not contain the necessary enzymatic machinery for the major oxidative metabolism of drugs. *Rough ER* - The **rough endoplasmic reticulum (RER)** is characterized by the presence of **ribosomes** and is mainly involved in the **synthesis, folding, modification, and transport of proteins** destined for secretion or insertion into membranes [2]. - While it plays a role in protein synthesis, it is not the primary site for drug oxidation. *Cytoplasm* - The cytoplasm contains various organelles and is the site of many metabolic pathways, including **glycolysis** and some **phase II drug metabolism** (e.g., glucuronidation, sulfation) [1]. - However, the bulk of phase I **oxidative drug metabolism** does not occur in the general cytoplasm but rather within the smooth ER due to the concentration of relevant enzymes there [1].

Q: Which drug is not administered as a transdermal patch?

Morphine. ***Morphine*** - **Morphine** is generally not administered transdermally due to its **poor lipid solubility** [1] and **large molecular size**, which limit its ability to penetrate the skin effectively. - While experimental patches have been developed, they are **not widely available** or commonly used in clinical practice for systemic delivery. *Fentanyl* - **Fentanyl** is a potent opioid that is commonly administered via a **transdermal patch** for chronic pain management [2]. - Its **high lipid solubility** and small molecular size allow it to be effectively absorbed through the skin, providing sustained analgesia. *Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist available as a **transdermal patch** for the treatment of **hypertension**. - The patch provides a **continuous and steady release** of the drug, leading to consistent blood pressure control. *Diclofenac* - **Diclofenac** is a non-steroidal anti-inflammatory drug (NSAID) available in **transdermal patch** formulations for topical pain relief. - These patches are used for localized pain conditions like **osteoarthritis** and provide targeted drug delivery with reduced systemic side effects.

Q: Maximum cycloplegic action of atropine is seen at ?

1-3 hours. ***1-3 hours*** - Atropine, a **non-selective muscarinic antagonist**, reaches its **peak cycloplegic effect** approximately 1 to 3 hours after topical administration. - This peak activity is crucial for accurate retinoscopy and **refractive error measurement** in children, as it effectively paralyzes the ciliary muscle. *4-6 hours* - While atropine's cycloplegic effect is still present at 4-6 hours, it is generally **past its peak action** by this time. - Slower-acting cycloplegics might have their peak around this window, but not atropine. *1-2 weeks* - The **duration of action** for atropine's cycloplegic and mydriatic effects can last for 1-2 weeks, but this is the total duration, not when the maximum action is observed. - Patients are often instructed about the **prolonged effects** and potential for blurred vision and photophobia over this period. *30-60 minutes* - While some mydriatic effects might start within 30-60 minutes, the **full cycloplegic effect** of atropine, which requires maximum paralysis of the ciliary muscle, is not achieved in this short timeframe. - Shorter-acting cycloplegics like **cyclopentolate** or **tropicamide** would show peak action within this earlier interval.

Q: Which of the following drug combinations demonstrates receptor level antagonism?

Isoprenaline (agonist) and Propranolol (antagonist). ***Isoprenaline (agonist) and Propranolol (antagonist)*** - **Propranolol** is a **beta-adrenergic receptor antagonist**, meaning it binds to and blocks beta-adrenergic receptors. - **Isoprenaline** is a **beta-adrenergic receptor agonist**, meaning it activates these same receptors. Their combined action demonstrates **receptor-level antagonism** as propranolol prevents isoprenaline from binding and eliciting its effect. *Histamine and Adrenaline* - This combination illustrates **physiological antagonism**, where two drugs produce opposite effects through different mechanisms and different receptors. - **Adrenaline** causes bronchodilation and vasoconstriction via adrenergic receptors, counteracting the effects of **histamine** (e.g., bronchoconstriction, vasodilation) which acts on histamine receptors. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **agonists** of adrenergic receptors, specifically beta-adrenergic receptors. - They would produce similar effects (e.g., increased heart rate, bronchodilation) rather than opposing each other at the receptor level. *None of the options* - This is incorrect because **Isoprenaline and Propranolol** is a valid example of receptor-level antagonism, making this option unnecessary.

Q: Which of the following drugs is NOT metabolized by acetylation?

Metoclopramide. ***Metoclopramide*** - **Metoclopramide** is eliminated primarily via renal excretion, with a smaller portion undergoing glucuronidation and sulfation, not acetylation. - Its metabolic pathway does not involve the enzyme **N-acetyltransferase**, which is responsible for acetylation. *Dapsone* - **Dapsone** undergoes significant **N-acetylation** by NAT2 (N-acetyltransferase 2), which is important for its metabolism and clearance. - Genetic variations in NAT2 can lead to individual differences in **dapsone acetylation rates**, affecting drug efficacy and toxicity. *Procainamide* - **Procainamide** is primarily metabolized by N-acetyltransferase 2 (NAT2) to **N-acetylprocainamide (NAPA)**, an active metabolite. - Differences in **acetylation phenotype** (slow vs. rapid acetylators) influence the metabolism of procainamide and the risk of drug-induced lupus. *INH* - **Isoniazid (INH)** is extensively metabolized in the liver, primarily by **N-acetylation** via the enzyme N-acetyltransferase 2 (NAT2). - The rate of INH acetylation varies significantly among individuals, classifying them as **slow or rapid acetylators**, which impacts drug toxicity and efficacy.

Question 1

Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

Accepted Answer

Dose-response relationship

Answer

Therapeutic index

Answer

Bioavailability

Answer

Phase 1 clinical trials

Question 2

A drug with high plasma protein binding property has which of the following properties?

Accepted Answer

Lower volume of distribution

Answer

Reduced renal clearance

Answer

Less drug interaction

Answer

Less tubular secretion

Question 3

When alcohol is consumed with aerated soft drinks -

Accepted Answer

Absorption is faster, increasing intoxication risk

Answer

Effect is enhanced

Answer

To reduce hangover risk

Answer

None of the options

Question 4

Which of the following statements represents the most clinically significant aspect of drug metabolism?

Accepted Answer

Most common enzyme involved is CYP 3A4/5

Answer

Glucuronidation is a phase II reaction

Answer

Reduction is a phase I reaction

Answer

Cytochrome P450 is involved in phase I reactions

Question 5

High volume of distribution is primarily determined by:

Accepted Answer

High lipid solubility

Answer

High plasma protein binding

Answer

Elimination rate

Answer

Half-life of the drug

Question 6

Where does the oxidation of drugs mainly take place?

Accepted Answer

Smooth ER

Answer

Rough ER

Answer

Cytoplasm

Answer

Nucleus

Question 7

Which drug is not administered as a transdermal patch?

Accepted Answer

Morphine

Answer

Fentanyl

Answer

Clonidine

Answer

Diclofenac

Question 8

Maximum cycloplegic action of atropine is seen at ?

Accepted Answer

1-3 hours

Answer

1-2 weeks

Answer

4-6 hours

Answer

30-60 minutes

Question 9

Which of the following drug combinations demonstrates receptor level antagonism?

Accepted Answer

Isoprenaline (agonist) and Propranolol (antagonist)

Answer

Histamine and Adrenaline

Answer

Adrenaline and Isoprenaline

Answer

None of the options

Question 10

Which of the following drugs is NOT metabolized by acetylation?

Accepted Answer

Metoclopramide

Answer

Dapsone

Answer

Procainamide

Answer

INH

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?